• UBE2F-SAG Mediated RHEB Neddylation Drives mTORC1 in Liver C

  2026-05-14

  This study identifies RHEB as a direct substrate for neddylation by the UBE2F-SAG axis, a modification that enhances mTORC1 signaling and promotes liver tumorigenesis. The mechanistic insights offer new targets for therapeutic intervention and highlight the intersection of post-translational modifications with cancer signaling networks.

• VX-702: Translating Dual-Action p38α MAPK Inhibition to Inno

  2026-05-13

  This article explores the mechanistic and translational power of VX-702, a highly selective p38α MAPK inhibitor, synthesizing structural insights, emerging dual-action paradigms, and practical guidance for inflammation and cardiovascular researchers. It delineates how VX-702’s unique mode of action not only suppresses cytokine signaling but also accelerates kinase dephosphorylation, offering new opportunities in experimental design and disease modeling.

• DAPT (GSI-IX) in Advanced Notch Signaling and Organoid Resea

  2026-05-13

  DAPT (GSI-IX) from APExBIO empowers precise and reproducible modulation of the Notch pathway and γ-secretase activity, catalyzing breakthroughs in disease modeling, regenerative medicine, and organoid technology. This guide unpacks hands-on workflows, troubleshooting tactics, and key innovations that set DAPT apart for translational research in neurodegeneration, cancer, and liver organogenesis.

• A Novel Anti-p16 AFDC: Selective Cytotoxicity in p16-High Tu

  2026-05-12

  This study reports the engineering and in vitro validation of a humanized anti-p16 antibody fragment-drug conjugate (AFDC) designed for selective cytotoxicity against p16-overexpressing cancer cells. By leveraging a single-chain variable fragment fused to a cell-penetrating peptide, the AFDC demonstrated potent, target-dependent efficacy in both cell lines and organoid models, highlighting its promise as a precision therapy for aggressive tumors with high p16 expression.

• Modeling Stroma-Driven Chemoresistance in Pancreatic Cancer

  2026-05-12

  Schuth et al. introduce a 3D organoid-fibroblast co-culture system that enables precise modeling of patient-specific stroma-mediated chemoresistance in pancreatic ductal adenocarcinoma (PDAC). This approach provides critical insights into how cancer-associated fibroblasts drive epithelial-to-mesenchymal transition and influence drug response, offering a new standard for preclinical drug screening and mechanistic research.

• Degarelix Acetate: Advanced GnRH Receptor Antagonist Workflo

  2026-05-11

  Degarelix acetate empowers researchers with rapid, selective hormone suppression, unlocking high-fidelity pituitary and prostate cancer models. This article details actionable experimental protocols, troubleshooting strategies, and innovations derived from the latest GnRH antagonist research. Discover data-driven insights to optimize your endocrine and oncology studies.

• CX-5461 Induces DNA Damage and Mitotic Catastrophe in Cervic

  2026-05-11

  This study demonstrates that the RNA polymerase I inhibitor CX-5461 suppresses cervical cancer cell proliferation by inducing DNA damage and mitotic catastrophe, while also enhancing cisplatin sensitivity. These findings highlight a mechanistically distinct approach for overcoming chemoresistance in cervical cancer models.

• GSTA1 Drives Glutathione Depletion in α-Amanitin Hepatotoxic

  2026-05-10

  This study reveals that GSTA1, typically an antioxidant enzyme, paradoxically worsens α-amanitin-induced liver injury by accelerating glutathione depletion and oxidative stress. The findings reposition GSTA1 as a direct therapeutic target and biomarker in acute hepatotoxicity, with significant implications for research into oxidative stress-driven pathologies.

• Ibrexafungerp (MK 3118): Redefining Antifungal Translation

  2026-05-09

  This thought-leadership article dissects the unique mechanistic and translational dimensions of Ibrexafungerp (MK 3118), the first oral triterpenoid antifungal targeting 1,3-β-D-glucan synthase, with a focus on resistant Candida. Drawing on rigorous in vitro and in vivo findings, including pivotal studies on Candida auris, we offer strategic guidance for translational researchers, clarify competitive differentiators, and chart a forward-looking perspective on antifungal innovation.

• Risedronate Sodium: Redefining Translational Strategies in B

  2026-05-09

  Explore how Risedronate Sodium’s dual action as a farnesyl pyrophosphate synthase inhibitor advances both bone metabolism and pulmonary disease research. This article integrates mechanistic insights, protocol guidance, and translational perspectives for researchers seeking robust, cross-domain applications.

• Inhibition of Renal OCT2 and MATE1 by 5-HT3 Antagonists: Ins

  2026-05-08

  This study systematically investigates the ability of five 5-HT3 receptor antagonists—including tropisetron—to inhibit renal drug transporters OCT2 and MATE1 in vitro. The findings illuminate the potential for drug-drug interactions affecting the renal elimination of cationic compounds, informing both neuroscience receptor modulation studies and pharmacokinetic risk assessments.

• p-Cresyl Sulfate Promotes Aortic Valve Calcification via Klo

  2026-05-07

  This study elucidates how p-cresyl sulfate (p-tolyl hydrogen sulfate), a uremic toxin, directly enhances calcification in aortic valvular interstitial cells by disrupting klotho and SIRT1 signaling. The findings connect chronic kidney disease pathology to calcific aortic valve disease and highlight klotho/SIRT1 as key regulatory nodes for future intervention.

• SC 79 Akt Activator: Optimizing Neuroprotection & Lipotoxici

  2026-05-07

  SC 79 is a unique small molecule Akt activator enabling precise, cytosolic Akt pathway modulation. This article translates bench research and reference breakthroughs into actionable workflows for neuroprotection and lipotoxicity studies, supported by data-driven troubleshooting and assay optimization advice.

• T-5224 (C-Fos/AP-1 inhibitor): Reliable Solutions for Inflam

  2026-05-06

  This article addresses key laboratory challenges in cell viability and inflammation assays, demonstrating how T-5224 (C-Fos/AP-1 inhibitor, SKU B4664) from APExBIO provides reproducible, data-driven solutions. Scenario-based guidance covers experimental design, assay optimization, data interpretation, and vendor selection to support researchers in arthritis and neuroinflammation models.

• Macrophage Niche Alterations Shape Kupffer Cell Plasticity i

  2026-05-06

  This study reveals that liver metastasis-associated macrophages (LMAMs) arise through both monocyte-derived and Kupffer cell-mediated mechanisms. Using sophisticated lineage tracing and proliferation-recording mouse models, the authors demonstrate that blocking monocyte recruitment prompts local proliferation and phenotypic reprogramming of resident Kupffer cells, sustaining an immunosuppressive microenvironment. These findings have critical implications for targeting myeloid cell plasticity in metastatic liver disease.

448 records 18/30 page Previous Next First page 上5页 1617181920 下5页 Last page